
TKNO — Alpha Teknova Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$7.08
-$0.10 (-1.39%)
Alpha Teknova Inc (TKNO) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Stephen Gunstream, based in 2451 Bert Dr., Hollister, CA, United States, 95023, with about 158 employees. Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Latest reported TKNO revenue for 2025-09-30 was $10.5M. Net income was -$4.3M. Revenue was up 1.6% from 2025-06-30 to 2025-09-30. TKNO currently screens at market cap $221.4M.
Use this TKNO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TKNO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TKNO SEC filings page. Lician reads the product cache first so this HTML stays unique to Alpha Teknova Inc even when a live quote feed is slow.
About Alpha Teknova Inc
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
TKNO Key Statistics
Market Cap
$221.43M
Volume
161,771
Previous Close
$7.34
Day Range
$7.21 – $7.51
P/B Ratio
3.41
EPS
-$0.57
Revenue
$37.74M
Net Income
-$26.75M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+2.9%
Profit Margin
-70.9%
Employees
158
TKNO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $37.74M | $36.68M | $41.42M | $36.89M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$26.75M | -$36.78M | -$47.47M | -$9.80M |
| EPS (Diluted) | -$0.57 | -$1.16 | -$1.69 | -$0.61 |
Total Assets
$118.77M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.71M
Operating Cash Flow
-$12.39M
Free Cash Flow
$0.00
Alpha Teknova Inc Company Information
- President, CEO & Director
- Stephen Gunstream
- Headquarters
- 2451 Bert Dr., Hollister, CA, United States, 95023
- Website
- www.teknova.com
- Phone
- 831 637 1100
- IPO / Founded
- 2021-06-25
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic